2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2

Journal of Medicinal Chemistry

Volumn 48, Issue 24, 2005, Pages 7560-7581

  Wissner, Allan ^a   Floyd, M Brawner ^a   Johnson, Bernard D ^a   Fraser, Heidi ^a   Ingalls, Charles ^a   Nittoli, Thomas ^a   Dushin, Russell G ^a   Discafani, Carolyn ^a   Nilakantan, Ramaswamy ^a   Marini, Joseph ^a   Ravi, Malini ^a   Cheung, Kinwang ^a   Tan, Xingzhi ^a   Musto, Sylvia ^a   Annable, Tami ^a   Siegel, Marshall M ^a   Loganzo, Frank ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2,5 DIMETHOXYPHENYL)(6,7 QUINAZOLIN 4 YL)AMINE; 2 (QUINAZOLIN 4 YLAMINO)[1,4]BENZOQUINONE DERIVATIVE; 2 CHLORO 5 (6,7 QUINAZOLIN 4 YLAMINO)[1,4]BENZOQUINONE DERIVATIVE; ALCOHOL; AMINE; AMMONIUM NITRATE; ANILINE DERIVATIVE; BENZOQUINONE DERIVATIVE; CHLORINE; GLUTATHIONE; PHENOL; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; COVALENT BOND; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOLECULAR MODEL; MOUSE; NONHUMAN; OXIDATION; SUBSTITUTION REACTION;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; ANIMALS; BENZOQUINONES; BINDING SITES; CELL LINE; FEMALE; GLUTATHIONE; HUMANS; KINETICS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUANTUM THEORY; QUINAZOLINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28144459983     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050559f     Document Type: Article

References (47)

1. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
2. Terman, B. I.; Dougher-Vermazen, M.; Carrion, M. E.; Dimitrov, D.; Armellino, D. C., Gospodarowicz, D.; Bohlen, P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187, 1579-1586.
3. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Sem. Oncol. 2002, 29, 15-18.
4. Ferrara, N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9 Suppl 1, 2-10.
5. Hicklin, D. J.; Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23, 1011-1027.
6. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13, 31-36.
7. Browder, T.; Butterfield, C. E.; Kraling, B. M.; Shi, B.; Marshall, B.; O'Reilly, M. S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Can. Res. 2000, 60, 1878-1886.
8. Kerbel, R. S.; Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev. Cancer 2004, 4, 423-436.
9. Ferrara, N.; Hillan, K. J.; Gerber, H. P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Dis. 2004, 3, 391-400.
10. Sweeney, P.; Karashima, T.; Kim, S. J.; Kedar, D.; Mian, B.; Huang, S., Baker, C.; Fan, Z.; Hicklin, D. J.; Pettaway, C. A.; Dinney, C. P. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin. Cancer Res. 2002, 8, 2714-2724.
11. Pavco, P. A.; Bouhana, K. S.; Gallegos, A. M.; Agrawal, A.; Blanchard, K. S.; Grimm, S. L.; Jensen, K. L.; Andrews, L. E.; Wincott, F. E.; Pitot, P. A.; Tressler, R. J.; Cushman, C.; Reynolds, M. A.; Parry, T. J. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. 2000, 6, 2094-2103.
12. Tokunaga, T.; Abe, Y.; Tsuchida, T.; Hatanaka, H.; Oshika, Y.; Tomisawa, M.; Yoshimura, M.; Ohnishi, Y.; Kijima, H.; Yamazaki, H.; Ueyama, Y.; Nakamura, M. Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int. J. Oncol. 2002, 21, 1027-1032.
13. Takei, Y.; Kadomatsu, K.; Yuzawa, Y.; Matsuo, S.; Muramatsu, T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004, 64, 3365-3370.
14. Underiner, T. L.; Ruggeri, B.; Gingrich, D. E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Cur. Med. Chem. 2004, 11, 731-745.
15. Boyer, S. J. Small molecule inhibitors of KDR (VEGFR-2) kinase: An overview of structure activity relationships. Curr. Top. Med. Chem. 2002, 2, 973-1000.
16. Laird, A. D.; Cherrington, J. M. Small molecule tyrosine kinase inhibitors: Clinical development of anticancer agents. Exp. Opin. Invest. Drugs 2003, 12, 51-64.
17. Steward, W. P.; Thomas, A.; Morgan, B.; Wiedenmann, B.; Bartel, C.; Vanhoefer, U.; Trarbach, T.; Junker, U.; Laurent, D. Lebwohl, D. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J. Clin. Oncol. (2004 ASCO Annual Meeting Proceedings) 2004, 22, 3556.
18. Raymond, E.; Faivre, S.; Vera, K.; Delbaldo, C.; Robert, C.; Spatz, A.; Bello, C.; Brega, N.; Scigalla, P.; Armand, J. P. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. 2003, 22, 192 (abstr 769).
19. Kabbinavar, F.; Hurwitz, H. I.; Fehrenbacher, L.; Meropol, N. J.; Novotny, W. F.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [see comment]. J. Clin. Oncol. 2003, 21, 60-65.
20. Johnson, D. H.; Fehrenbacher, L.; Novotny, W. F.; Herbst, R. S.; Nemunaitis, J. J.; Jablons, D. M.; Langer, C. J.; DeVore, R. F., III; Gaudreault, J.; Damico, L. A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184-2191.
21. Torrance, C. J.; Jackson, P. E.; Montgomery, E.; Wissner, A.; Kinzler, K. W.; Vogelstein, B.; Frost, P.; Discafani, C. M. Combinatorial Chemoprevention of Intestinal Neoplasia. Nat. Med. 2000, 6, 1024-1028.
22. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R., Wang, Y.-F.; Greenberger, L. M.; Tsou, H.-R. Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2). J. Med. Chem. 2003, 46, 49-63.
23. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H.-R.; Wang, Y.-F.; Wissner, A. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase. Cancer Res. 2004, 64, 3958-3965.
24. Tsou, H.-R.; Overbeek, E.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y.-F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-Disubstituted-4(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of HER-2 kinase Activity. J. Med. Chem. 2005, 48, 1107-1131.
25. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C. C.; Villafranca, J. E.; Appelt, K. Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis. Struct. Fold Des. 1999, 7, 319-330.
26. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S. E.; Plé, P. A.; Lohmann, J.-J. M.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R. Curwen,; J. O.; Kendrew; Lambert-van der Brempt, C. Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 1999, 42, 5369-5389.
27. Wissner, A.; Berger, D. M.; Boschelli, D. H.; Floyd, M. B. Jr., Greenberger, L. M.; Gruber, B. C.; Johnson, B. D.; Mamuya, N.; Nilakantan, R.; Reich, M. F.; Shen, R.; Tsou, H.-R.; Upeslacis, E.; Wang, Y.-F.; Wu, B.; Ye, F.; Zhang, N. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile Inhibitors of Epidermal Growth Factor Receptor (EGF-R) Kinase and Their Bioisosteric Relationship to the 4-Anilino-6,7-dialkoxyquinazoline Inhibitors. J. Med. Chem. 2000, 43, 3244-3256.
28. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase. J. Med. Chem. 2000, 43, 133-138.
29. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor. J. Biol. Chem. 2002, 277, 46265-46272.
30. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Curwen, J. O.; Hennequin, L. F.; Thomas, A. P.; Stokes, E. S. E.; Curry, B.; Richmond, G. H. P.; Wadsworth, P. F. ZD4190: An Orally Active Inhibitor of Vascular Endothelial Growth Factor Signaling with Broad-spectrum Antitumor Efficacy. Cancer Res. 2000, 60, 970-975.
31. Borgulya, J.; Bruderer, H.; Bernauer, K.; Zuercher, G.; Mose, D.-P. Catechol-O-methyltransferase-inhibiting Pyrocatechol Derivatives: Synthesis and Structure-Activity Studies. Helv. Chim. Acta 1989, 72, 952-968.
32. Wissner, A.; Floyd, M. B; Rabindran, S. K.; Nilakantan, R.; Greenberger, L. M.; Shen, R.; Wang, Y.-F.; Tsou, H.-R. Syntheses and EGFR and HER-2 Kinase Inhibitory Activities of 4-Anilinoquinoline-3-Carbonitriles. Analogues of Three Important 4-A-nilinoquinazolines Currently Undergoing Clinical Evaluation as Therapeutic Antitumor Agents. Bioorg. Med. Chem. Lett. 2002, 12, 2893-2897.
33. Barker, A. J.; Brown, D. S. Preparation of Aminoquinazolines Useful in the Treatment of Cancer. Eur. Pat. Appl. EP602851, 1994.
34. Magee, P. S. Exploring the Chemistry of Quinones by Computation. Quant. Struct. Act. Relat. 2000, 19, 22-28.
35. Rozeboom, M. D.; Tegmo-Larsson, I.-M.; Houk, K. N. Frontier Molecular Orbital Theory of Substituent Effects on Regioselectivities of Nucleophilic Additions and Cycloadditions to Benzoquinones and Naphthoquinones. J. Org. Chem. 1981, 46, 2338-2345.
36. Takahashi, N.; Schreiber, J.; Fischer, V.; Mason, R. P. Formation of Glutathione-Conjugated Semiquinones by the Reaction of Quinones with Glutathione: An ESR Study. Arch. Biochem. Biophys. 1987, 252, 41-48.
37. FRED; Open Eye Scientific Software: Santa Fe, NM (www.eyesopen.com)
38. Rush, T. S.; III.; Manas, E.; Tawa, G.; and Alvarez, J. Solvation-Based Scoring for High Throughput Docking in Virtual Screening in Drug Discovery; Alvarez, J. and Shoichet, B., Eds.; CRC Press: Boca Raton, FL, 2005; pp 241-269.
39. Loganzo, F. and Hardy, C. A A Sensitive, Time-resolved Fluorometric Assay for Detection of Inhibitors of Phosphotyrosine Kinases. Am. Biotech. Lab. 1998, 16, 26-28.
40. Hennequin, L. F.; Stokes, E. S. E.; Thomas, A. P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
41. Bold, G.; Altmann, K.-H.; Bruggen, J.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyss, D.; Wood, J. M. New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
42. Dougher, M.; I. Terman, B. I. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 1999, 18, 1619-1627.
43. Sybyl 6.9; Tripos, Inc : St. Louis, MO.
44. OMEGA; Open Eye Scientific Software: Santa Fe, NM.
45. Davidson, N. Statistical Mechanics; McGraw-Hill: New York, 1962.
46. McQuarrie, D. A. Statistical Mechanics; Harper & Row Inc., New York, 1976.
47. Butenandt, A.; Biekert, E.; Haerle, E. Preparation and conversions of 4,5,8-trihydroxy-6-mercaptoquinoline-2-carboxylic acid. Chem. Ber. 1964, 97, 285-294.